A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
Recruiting in Palo Alto (17 mi)
Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Eli Lilly and Company
Approved in 6 jurisdictions
Trial Summary
What is the purpose of this trial?This trial tests tirzepatide in people with obesity to see how it affects calorie burning and food intake. The study lasts several months and involves multiple visits to the study center. Tirzepatide is a new treatment effective in managing obesity and type 2 diabetes.
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 15 Milligram (mg) TirzepatideExperimental Treatment1 Intervention
Participants received 15 mg of tirzepatide QW by SC injection.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
Tirzepatide is already approved in United States, European Union, Canada, Australia, United States, United Kingdom for the following indications:
🇺🇸 Approved in United States as Mounjaro for:
- Type 2 diabetes
🇪🇺 Approved in European Union as Mounjaro for:
- Type 2 diabetes
🇨🇦 Approved in Canada as Mounjaro for:
- Type 2 diabetes
🇦🇺 Approved in Australia as Mounjaro for:
- Type 2 diabetes
🇺🇸 Approved in United States as Zepbound for:
- Weight loss
- Moderate to severe obstructive sleep apnea
🇬🇧 Approved in United Kingdom as Zepbound for:
- Weight loss
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Pennington Biomedical Research CenterBaton Rouge, LA
Loading ...
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor